公开(公告)号：JP2004091495A

公开(公告)日：2004-03-25

申请号：JP2003377620

申请日：2003-11-06

Applicant: Pharmacyclics Inc ,  Univ Texas Syst ,  ファーマサイクリクス,インコーポレイテッド ,  ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents,The University Of Texas System

Inventor： SESSLER JONATHAN L ,  HARRIMAN ANTHONY M ,  MILLER RICHARD A ,  MODY TARAK D ,  HEMMI GREGORY W ,  KRAAL VLADIMIR A ,  MAGDA DARREN

IPC: A61K31/40 ,  A61K31/407 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/06 ,  A61K49/08 ,  A61K51/00 ,  A61K51/04 ,  A61L2/00 ,  A61P35/02 ,  A61P43/00 ,  B01J31/06 ,  B01J31/16 ,  B01J31/18 ,  C07D487/22 ,  C07H21/00

CPC classification number: A61K51/0485 ,  A61K41/0038 ,  A61K41/0057 ,  A61K41/0076 ,  A61K47/546 ,  A61K49/0021 ,  A61K49/0054 ,  A61K49/085 ,  A61K49/10 ,  A61K49/106 ,  A61K49/126 ,  A61L2/0011 ,  B01J31/061 ,  B01J31/1658 ,  B01J31/1805 ,  B01J31/1815 ,  B01J2531/025 ,  B01J2531/23 ,  B01J2531/26 ,  B01J2531/27 ,  B01J2531/28 ,  B01J2531/36 ,  B01J2531/37 ,  B01J2531/38 ,  B01J2531/72 ,  B01J2531/842 ,  B01J2531/845 ,  B01J2531/847 ,  B01J2531/96 ,  C07D487/22 ,  C07H21/00

Abstract: PROBLEM TO BE SOLVED: To obtain texaphyrin for radiosensitization. SOLUTION: A medicinal composition used for a radiosensitizer is prepared by using the texaphyrin. The texaphyrin is an aromatic 5 position (and heptacyclic) macrocycle (enlarged porphyrin) and, may be due to its inherent lipophilic property, shows larger biolocalization in non-neoplasm organs and non-atheroma plaque in neoplasm organ and atheroma each possible to be a malignant or benign tumor. The texaphyrin improves radiation damage and overcomes many defects of conventional radiosensitizers. COPYRIGHT: (C)2004,JPO

公开(公告)号：WO9429316A3

公开(公告)日：1995-02-02

申请号：PCT/US9406284

申请日：1994-06-09

Applicant: UNIV TEXAS ,  PHARMACYCLICS INC ,  SESSLER JONATHAN L ,  ROSS KEVIN L ,  WRIGHT MEREDITH ,  HEMMI GREGORY W ,  DOW WILLIAM C ,  SMITH DANIEL A ,  KRAL VLADIMIR A ,  IVERSON BRENT ,  MODY TARAK ,  MILLER RICHARD A ,  MAGDA DARREN

Inventor： SESSLER JONATHAN L ,  ROSS KEVIN L ,  WRIGHT MEREDITH ,  HEMMI GREGORY W ,  DOW WILLIAM C ,  SMITH DANIEL A ,  KRAL VLADIMIR A ,  IVERSON BRENT ,  MODY TARAK ,  MILLER RICHARD A ,  MAGDA DARREN

IPC: A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/06 ,  A61K49/08 ,  A61K51/04 ,  A61L2/00 ,  B01J31/06 ,  B01J31/16 ,  B01J31/18 ,  C07B61/00 ,  C07D487/22 ,  C07F9/06 ,  C07F9/6558 ,  C07F9/6561 ,  C07H21/00 ,  C12N15/10 ,  C12Q1/68

CPC classification number: C07D487/22 ,  A61K41/0038 ,  A61K41/0076 ,  A61K47/546 ,  A61K49/0021 ,  A61K49/0036 ,  A61K49/085 ,  A61K49/106 ,  A61K49/126 ,  A61K51/0485 ,  A61L2/0011 ,  B01J31/061 ,  B01J31/1658 ,  B01J31/1815 ,  B01J2531/025 ,  B01J2531/23 ,  B01J2531/26 ,  B01J2531/27 ,  B01J2531/28 ,  B01J2531/38 ,  B01J2531/72 ,  B01J2531/842 ,  B01J2531/845 ,  B01J2531/847 ,  B01J2531/96 ,  C07H21/00

Abstract: A method of phosphate ester hydrolysis including incubating a solution of an aqueous phosphate ester with a texaphyrin metal complex. The metal is a metal cation having catalytic activity for ester bond hydrolysis in aqueous solution, in particular, a lanthanide metal cation, preferably Eu(III) or Dy(III). A preferred substrate is RNA and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directed molecule, preferably an oligonucleotide.

公开(公告)号：WO9825648A3

公开(公告)日：1999-12-09

申请号：PCT/US9722661

申请日：1997-12-11

Applicant: PHARMACYCLICS INC ,  BLUMENKRANZ MARK S ,  WOODBURN KATHRYN W ,  MILLER RICHARD A ,  YOUNG STUART W

Inventor： BLUMENKRANZ MARK S ,  WOODBURN KATHRYN W ,  MILLER RICHARD A ,  YOUNG STUART W

IPC: A61B3/14 ,  A61K31/409 ,  A61K41/00 ,  A61K49/00 ,  A61K49/04 ,  A61P27/02 ,  C07D259/00

CPC classification number: A61K49/0036 ,  A61K41/0076

Abstract: The use of texaphyrins for ocular diagnosis and therapy is provided, especially use of photosensitive texaphyrins for photodynamic therapy of conditions of the eye characterized by abnormal vasculature, such as macular degeneration, or pterygium, for example. The photosensitive texaphyrin may be a free-base texaphyrin or may be metallated with a diamagnetic metal. Preferably, the photosensitive texaphyrin is metallated with lutetium. Due to the dual wavelength absorption of texaphyrins, i.e., at 400-500 nm and at 700-800 nm, especially about 732 nm, as compared to porphyrins, texaphyrins are more effective and versatile for use in humans as compared to porphyrins. Texaphyrins serve as effective contrast agents in ocular angiography.

Abstract translation: 提供了泰克萨菲瑞用于眼部诊断和治疗的用途，特别是使用光敏泰克萨菲瑞用于光动力学治疗眼睛状况的特征是例如黄斑变性或翼状by肉的异常脉管系统。 感光性泰克萨菲瑞可以是游离碱泰克萨菲瑞，也可以用抗磁性金属进行金属化。 优选地，感光性泰克萨菲瑞用镥金属化。 由于与卟啉相比，泰克萨菲瑞的双波长吸收，即在400-500nm和700-800nm，特别是约732nm，与卟啉相比，泰克萨菲瑞对于人类更有效和通用。 Texaphyrins作为眼部血管造影术中的有效造影剂。

公开(公告)号：EP1465617A4

公开(公告)日：2005-10-12

申请号：EP02799240

申请日：2002-12-12

Applicant: PHARMACYCLICS INC

Inventor： MILLER RICHARD A

IPC: C07D487/22 ,  A61K31/407 ,  A61K31/555 ,  A61K47/48 ,  A61P25/00 ,  A61P25/28 ,  A61P35/00 ,  A61P35/02 ,  A61K31/33

CPC classification number: A61K31/555 ,  A61K47/546 ,  A61K47/60

公开(公告)号：ES2315429T3

公开(公告)日：2009-04-01

申请号：ES02799240

申请日：2002-12-12

Applicant: PHARMACYCLICS INC

Inventor： MILLER RICHARD A

IPC: A61K31/33 ,  C07D487/22 ,  A61K31/407 ,  A61K31/555 ,  A61K47/48 ,  A61P25/00 ,  A61P25/28 ,  A61P35/00 ,  A61P35/02

Abstract: Uso de un compuesto de Fórmula I (Ver fórmula) para preparar un medicamento útil para retrasar/ralentizar selectivamente la progresión neurológica en un ser humano aquejado de cáncer pulmonar y metástasis cerebrales de dicho cáncer pulmonar.

公开(公告)号：DK1465617T3

公开(公告)日：2009-02-16

申请号：DK02799240

申请日：2002-12-12

Applicant: PHARMACYCLICS INC

Inventor： MILLER RICHARD A

IPC: A61K31/33 ,  C07D487/22 ,  A61K31/407 ,  A61K31/555 ,  A61K47/48 ,  A61P25/00 ,  A61P25/28 ,  A61P35/00 ,  A61P35/02

Abstract: The present invention relates to use of a compound of Formula I: for improving neurologic functions in patients afflicted with systemic lung cancer that has metastasized to the brain (brain metastases).

公开(公告)号：DE60229437D1

公开(公告)日：2008-11-27

申请号：DE60229437

申请日：2002-12-12

Applicant: PHARMACYCLICS INC

Inventor： MILLER RICHARD A

IPC: A61K31/33 ,  C07D487/22 ,  A61K31/407 ,  A61K31/555 ,  A61K47/48 ,  A61P25/00 ,  A61P25/28 ,  A61P35/00 ,  A61P35/02

Abstract: The present invention relates to use of a compound of Formula I: for improving neurologic functions in patients afflicted with systemic lung cancer that has metastasized to the brain (brain metastases).

公开(公告)号：CA2173319C

公开(公告)日：2008-03-25

申请号：CA2173319

申请日：1994-10-12

Applicant: UNIV TEXAS ,  PHARMACYCLICS INC

Inventor： SESSLER JONATHAN L ,  HARRIMAN ANTHONY M ,  MILLER RICHARD A ,  MODY TARAK D ,  HEMMI GREGORY W ,  KRAL VLADIMIR A ,  MAGDA DARREN

IPC: C07D487/22 ,  A61K31/40 ,  A61K31/407 ,  A61K31/555 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/06 ,  A61K49/08 ,  A61K51/00 ,  A61K51/04 ,  A61L2/00 ,  A61P35/02 ,  A61P43/00 ,  B01J31/06 ,  B01J31/16 ,  B01J31/18 ,  C07H21/00

Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.

公开(公告)号：ES2227671T3

公开(公告)日：2005-04-01

申请号：ES97903873

申请日：1997-01-23

Applicant: PHARMACYCLICS INC

Inventor： MILLER RICHARD A ,  YOUNG STUART W

IPC: C07D487/22 ,  A61K31/00 ,  A61K31/40 ,  A61K31/555 ,  A61K31/675 ,  A61K33/24 ,  A61K38/14 ,  A61K41/00 ,  A61P35/00 ,  A61P35/02 ,  A61P43/00

Abstract: SE PRESENTAN METODOS DE QUIMIOSENSIBILIZACION DEL CANCER. LAS TEXAFIRINAS SON NUEVOS QUIMIOSENSIBILIZADORES PARA AUMENTAR LA CITOTOXICIDAD DE LOS AGENTES QUIMIOTERAPEUTICOS. LA MEJORA PARECE SER INDEPENDIENTE DE LAS P - GLUCOPROTEINAS YA QUE LAS TEXAFIRINAS SON EFECTIVAS TANTO EN UNA LINEA CELULAR QUE EXPRESA P - GLUCOPROTEINAS COMO EN UNA QUE NO EXPRESA P - GLUCOPROTEINAS. SE PRESENTAN METODOS PARA EL TRATAMIENTO DE CANCERES TALES COMO LA LEUCEMIA, LINFOMAS, CARCINOMAS Y SARCOMAS MEDIANTE LA UTILIZACION DE UNA TEXAFIRINA COMO QUIMIOSENSIBILIZADOR.

公开(公告)号：AT240745T

公开(公告)日：2003-06-15

申请号：AT97954554

申请日：1997-12-11

Applicant: PHARMACYCLICS INC

Inventor： BLUMENKRANZ MARK S ,  WOODBURN KATHRYN W ,  MILLER RICHARD A ,  YOUNG STUART W

IPC: A61B3/14 ,  A61K31/409 ,  A61K41/00 ,  A61K49/00 ,  A61K49/04 ,  A61P27/02 ,  C07D259/00 ,  A61P27/00

Abstract: The use of texaphyrins for ocular diagnosis and therapy is provided, especially use of photosensitive texaphyrins for photodynamic therapy of conditions of the eye characterized by abnormal vasculature, such as macular degeneration, or pterygium, for example. The photosensitive texaphyrin may be a free-base texaphyrin or may be metallated with a diamagnetic metal. Preferably, the photosensitive texaphyrin is metallated with lutetium. Due to the dual wavelength absorption of texaphyrins, i.e., at 400-500 nm and at 700-800 nm, especially about 732 nm, as compared to porphyrins, texaphyrins are more effective and versatile for use in humans as compared to porphyrins. Texaphyrins serve as effective contrast agents in ocular angiography.